Trials / Completed
CompletedNCT05502562
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
A Multicentre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Initiation of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in India
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 388 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor. The study will last for about 8-11 months (34-44 weeks). Participants will be asked to complete a questionnaire about how they take oral semaglutide tablets. Participants will complete this questionnaire during the normal scheduled visit with the doctor and will be asked questions about their health and their diabetes treatment and lab tests as part of their normal doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral semaglutide | Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study. |
Timeline
- Start date
- 2023-02-24
- Primary completion
- 2024-06-03
- Completion
- 2024-06-03
- First posted
- 2022-08-16
- Last updated
- 2024-09-19
Source: ClinicalTrials.gov record NCT05502562. Inclusion in this directory is not an endorsement.